221 related articles for article (PubMed ID: 38650460)
1. Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.
Carta V; Mangeri L; Tiecco G; Focà E; Quiros-Roldan E; De Francesco MA
Hum Vaccin Immunother; 2024 Dec; 20(1):2341456. PubMed ID: 38650460
[TBL] [Abstract][Full Text] [Related]
2. Varicella Virus Vaccination in the United States.
Shaw J; Gershon AA
Viral Immunol; 2018 Mar; 31(2):96-103. PubMed ID: 29173081
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for preventing herpes zoster in older adults.
de Oliveira Gomes J; Gagliardi AM; Andriolo BN; Torloni MR; Andriolo RB; Puga MEDS; Canteiro Cruz E
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD008858. PubMed ID: 37781954
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.
Gershon AA; Levin MJ; Weinberg A; Song LY; LaRussa PS; Steinberg SP; Bartlett P;
Pediatr Infect Dis J; 2009 Jul; 28(7):653-5. PubMed ID: 19561431
[TBL] [Abstract][Full Text] [Related]
5. Strategies for herpes zoster vaccination of immunocompromised patients.
Cohen JI
J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S237-41. PubMed ID: 18419403
[TBL] [Abstract][Full Text] [Related]
6. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
[TBL] [Abstract][Full Text] [Related]
9. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
10. Th1 memory differentiates recombinant from live herpes zoster vaccines.
Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
[TBL] [Abstract][Full Text] [Related]
11. Varicella and herpes zoster vaccine development: lessons learned.
Warren-Gash C; Forbes H; Breuer J
Expert Rev Vaccines; 2017 Dec; 16(12):1191-1201. PubMed ID: 29047317
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children.
Taweesith W; Puthanakit T; Kowitdamrong E; Bunupuradah T; Wongngam W; Phasomsap C; Apornpong T; Bouko C; Pancharoen C
Pediatr Infect Dis J; 2011 Apr; 30(4):320-4. PubMed ID: 20975615
[TBL] [Abstract][Full Text] [Related]
14. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older.
Levine MJ; Ellison MC; Zerbe GO; Barber D; Chan C; Stinson D; Jones M; Hayward AR
Vaccine; 2000 Jun; 18(25):2915-20. PubMed ID: 10812235
[TBL] [Abstract][Full Text] [Related]
16. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
17. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.
Weinberg A; Levin MJ; Macgregor RR
Hum Vaccin; 2010 Apr; 6(4):318-21. PubMed ID: 20372089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
